News
Feed
Events
Feed
News
+ Events
Feed

Kuros Biosciences AG

  • ISIN CH0325814116
  • Land Schweiz

Aktuelle News

13 März 2024

07:00 Ad-hoc EN

Kuros Biosciences AG

Ad-hoc
EN

Kuros reports 163% growth in direct MagnetOs sales and 153% increase in total medical device sales for the full year 2023

8 März 2024

07:00 Corporate EN

Kuros Biosciences AG

Corporate
EN

Kuros Biosciences to Report Full Year Financial Results for 2023 and Provide Corporate Update

1 Februar 2024

07:00 Corporate EN

Kuros Biosciences AG

Corporate
EN

Kuros Biosciences to Present at the CG 2024 Musculoskeletal Conference

31 Januar 2024

07:00 Corporate EN

Kuros Biosciences AG

Corporate
EN

Kuros Biosciences Receives US FDA 510K Clearance for MagnetOs Granules for Interbody Use and Regulatory Clearance of MagnetOs Granules and MagnetOs Putty in New Zealand

4 Januar 2024

07:00 Corporate EN

Kuros Biosciences AG

Corporate
EN

Kuros Biosciences Announces Three Advancements Related to its MagnetOsTM Portfolio Including Impressive Fusion Data from MAXA Prospective Randomized Clinical Trial and Two 510(k) Clearances from FDA

27 Dezember 2023

07:00 Ad-hoc EN

Kuros Biosciences AG

Ad-hoc
EN

Kuros Biosciences Announces Results from Two Prospective Randomized Clinical Trials: STRUCTURE and MAXA

28 November 2023

18:00 Corporate EN

Kuros Biosciences AG

Corporate
EN

Kuros Biosciences Receives FDA Clearance for Use of MagnetOs in Interbody Spinal Cages

12 Oktober 2023

07:00 Ad-hoc EN

Kuros Biosciences AG

Ad-hoc
EN

Kuros reports a 150% increase in direct MagnetOs sales in the first nine months of 2023 and announces changes within the Executive Management

9 August 2023

07:00 Ad-hoc EN

Kuros Biosciences AG

Ad-hoc
EN

Kuros Biosciences Reports Results for First Half 2023

13 Juli 2023

19:29 Corporate EN

Kuros Biosciences AG

Corporate
EN

Kuros Biosciences Announces Completion of Enrollment in the Fibrin-PTH Phase 2 Trial

8 Mai 2023

17:18 Ad-hoc EN

Kuros Biosciences AG

Ad-hoc
EN

Annual General Meeting of Kuros Biosciences approves all resolutions

27 April 2023

07:00 Ad-hoc EN

Kuros Biosciences AG

Ad-hoc
EN

Kuros reports 168% increase in direct MagnetOs sales in the first quarter of 2023

15 März 2023

07:00 Ad-hoc EN

Kuros Biosciences AG

Ad-hoc
EN

Kuros Biosciences reports results for the full year 2022

21 Februar 2023

07:00 Corporate EN

Kuros Biosciences AG

Corporate
EN

Kuros Biosciences Announces Publication of Supportive Osteoimmunology Data for MagnetOs Bone Graft

16 Februar 2023

18:01 Ad-hoc EN

Kuros Biosciences AG

Ad-hoc
EN

Kuros Biosciences Announces Changes to Executive Management Team

23 November 2022

07:00 Corporate EN

Kuros Biosciences AG

Corporate
EN

Kuros Biosciences Completes Enrollment of Randomized Stage of Phase 2 Trial for Fibrin-PTH

2 November 2022

07:00 Corporate EN

Kuros Biosciences AG

Corporate
EN

Kuros Biosciences completes enrolment in Level 1 clinical study of MagnetOs Granules

26 Oktober 2022

07:00 Ad-hoc EN

Kuros Biosciences AG

Ad-hoc
EN

Kuros reports 73% increase in MagnetOs sales in first nine months of 2022

19 Oktober 2022

07:00 Corporate EN

Kuros Biosciences AG

Corporate
EN

Kuros Biosciences awarded 2022 Spine Technology Award for MagnetOs Flex Matrix by Orthopedics This Week

11 Oktober 2022

07:00 Corporate EN

Kuros Biosciences AG

Corporate
EN

Kuros Biosciences to present positive clinical data for MagnetOs at NASS 2022 Annual Meeting

07:00 Corporate EN

Kuros Biosciences AG

Corporate
EN

Kuros Biosciences to present positive clinical data for MagnetOs at NASS 2022 Annual Meeting

3 Oktober 2022

07:00 Ad-hoc EN

Kuros Biosciences AG

Ad-hoc
EN

Kuros Biosciences Appoints Chris Fair as Chief Operating Officer

15 September 2022

07:00 Ad-hoc EN

Kuros Biosciences AG

Ad-hoc
EN

Kuros Biosciences announces successful CHF 6.0 million private placement

23 August 2022

07:00 Corporate EN

Kuros Biosciences AG

Corporate
EN

Kuros Biosciences’ MagnetOs Bone Graft Successfully Achieves Three Key Milestones

9 August 2022

17:50 Ad-hoc EN

Kuros Biosciences AG

Ad-hoc
EN

Kuros Biosciences reports results for the first six months of 2022

8 Juni 2022

19:00 Ad-hoc EN

Kuros Biosciences AG

Ad-hoc
EN

Annual General Meeting of Kuros Biosciences approves all resolutions

2 Juni 2022

07:00 Ad-hoc EN

Kuros Biosciences AG

Ad-hoc
EN

Kuros Biosciences: Completion of the acquisition of Checkmate Pharmaceuticals by Regeneron Pharmaceuticals triggers a $5 million milestone payment

31 Mai 2022

07:00 Corporate EN

Kuros Biosciences AG

Corporate
EN

Kuros Biosciences announces favorable preliminary results of MagnetOs as standalone alternative to autograft in first randomized controlled trial

18 Mai 2022

07:00 Corporate EN

Kuros Biosciences AG

Corporate
EN

Kuros Biosciences announces commercial launch of MagnetOs Easypack Putty in the U.S.

27 April 2022

08:07 Ad-hoc EN

Kuros Biosciences AG

Ad-hoc
EN

Kuros Biosciences continues strong commercial roll-out of MagnetOs bone graft

Anstehende Events

Keine Events gefunden